Literature DB >> 16015690

Thermo-chemo-radiotherapy for advanced bile duct carcinoma.

Terumi Kamisawa1, Yuyang Tu, Naoto Egawa, Katsuyuki Karasawa, Tadayoshi Matsuda, Kouji Tsuruta, Atsutake Okamoto.   

Abstract

AIM: Complete resection of the bile duct carcinoma is sometimes difficult by subepithelial spread in the duct wall or direct invasion of adjacent blood vessels. Nonresected extrahepatic bile duct carcinoma has a dismal prognosis, with a life expectancy of about 6 mo to 1 year. To improve the treatment results of locally advanced bile duct carcinoma, we have been conducting a clinical trial using regional hyperthermia in combination with chemoradiation therapy.
METHODS: Eight patients complaining of obstructive jaundice with advanced extrahepatic bile duct underwent thermo-chemo-radiotherapy (TCRT). All tumors were located in the upper bile duct and involved hepatic bifurcation, and obstructed the bile duct completely. Radiofrequency capacitive hyperthermia was administered simultaneously with chemotherapeutic agents once weekly immediately following radiotherapy at 2 Gy. We administered heat to the patient for 40 min after the tumor temperature had risen to 42 degrees C. The chemotherapeutic agents employed were cis-platinum (CDDP, 50 mg/m(2)) in combination with 5-fluorouracil (5-FU, 800 mg/m(2)) or methotrexate (MTX, 30 mg/m(2)) in combination with 5-FU (800 mg/m(2)). Number of heat treatments ranged from 2 to 8 sessions. The bile duct at autopsy was histologically examined in three patients treated with TCRT.
RESULTS: In respect to resolution of the bile duct, there were three complete regression (CR), two partial regression (PR), and three no change (NC). Mean survival was 13.2+/-10.8 mo (mean+/-SD). Four patients survived for more than 20 mo. Percutaneous transhepatic biliary drainage (PTBD) tube could be removed in placement of self-expandable metallic stent into the patency-restored bile duct after TCRT. No major side effects occurred. At autopsy, marked hyalinization or fibrosis with necrosis replaced extensively bile duct tumor and wall, in which suppressed cohesiveness of carcinoma cells and degenerative cells were sparsely observed.
CONCLUSION: Although the number of cases is rather small, TCRT in the treatment of locally advanced bile duct carcinoma is promising in raising local control and thus, long-term survival.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16015690      PMCID: PMC4615443          DOI: 10.3748/wjg.v11.i27.4206

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  16 in total

1.  One versus four heat treatments in combination with radiotherapy in metastatic mammary carcinoma.

Authors:  G Arcangeli; C Casale; F Colistro; M Benassi; G Lovisolo; L Begnozzi
Journal:  Int J Radiat Oncol Biol Phys       Date:  1991-11       Impact factor: 7.038

2.  Effect of hyperthermia on malignant cells in vivo. A review and a hypothesis.

Authors:  J Overgaard
Journal:  Cancer       Date:  1977-06       Impact factor: 6.860

3.  Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group.

Authors:  J van der Zee; D González González; G C van Rhoon; J D van Dijk; W L van Putten; A A Hart
Journal:  Lancet       Date:  2000-04-01       Impact factor: 79.321

Review 4.  What constitutes long-term survival after surgery for hilar cholangiocarcinoma?

Authors:  J Klempnauer; G J Ridder; M Werner; A Weimann; R Pichlmayr
Journal:  Cancer       Date:  1997-01-01       Impact factor: 6.860

5.  The development and extension of hepatohilar bile duct carcinoma. A three-dimensional tumor mapping in the intrahepatic biliary tree visualized with the aid of a graphics computer system.

Authors:  M Suzuki; T Takahashi; K Ouchi; S Matsuno
Journal:  Cancer       Date:  1989-08-01       Impact factor: 6.860

6.  Effect of local hyperthermia on blood flow and microenvironment: a review.

Authors:  C W Song
Journal:  Cancer Res       Date:  1984-10       Impact factor: 12.701

7.  Radiofrequency capacitive hyperthermia for deep-seated tumors. II. Effects of thermoradiotherapy.

Authors:  M Hiraoka; S Jo; K Akuta; Y Nishimura; M Takahashi; M Abe
Journal:  Cancer       Date:  1987-07-01       Impact factor: 6.860

8.  Long-term effects of hyperthermia combined with chemotherapy and irradiation for the treatment of patients with carcinoma of the esophagus.

Authors:  K Sugimachi; H Matsuda; S Ohno; A Fukuda; H Matsuoka; M Mori; H Kuwano
Journal:  Surg Gynecol Obstet       Date:  1988-10

9.  Quality assurance problems in clinical hyperthermia and their impact on therapeutic outcome: a Report by the Radiation Therapy Oncology Group.

Authors:  C A Perez; B Gillespie; T Pajak; N B Hornback; B Emami; P Rubin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-03       Impact factor: 7.038

10.  Tumor control and therapeutic gain with different schedules of combined radiotherapy and local external hyperthermia in human cancer.

Authors:  G Arcangeli; A Cividalli; C Nervi; G Creton; G Lovisolo; F Mauro
Journal:  Int J Radiat Oncol Biol Phys       Date:  1983-08       Impact factor: 7.038

View more
  3 in total

1.  Intrabiliary RF heat-enhanced local chemotherapy of a cholangiocarcinoma cell line: monitoring with dual-modality imaging--preclinical study.

Authors:  Feng Zhang; Thomas Le; Xia Wu; Han Wang; Tong Zhang; Yanfeng Meng; Baojie Wei; Stephanie S Soriano; Patrick Willis; Orpheus Kolokythas; Xiaoming Yang
Journal:  Radiology       Date:  2013-11-08       Impact factor: 11.105

2.  Patient With Unresectable Cholangiocarcinoma Treated With Radiofrequency Hyperthermia in Combination With Chemotherapy: A Case Report.

Authors:  Juyoung Ryu; Kangwook Lee; Changmug Joe; JongCheon Joo; Namhun Lee; Hwa-Seung Yoo
Journal:  Integr Cancer Ther       Date:  2017-07-26       Impact factor: 3.279

3.  Radiofrequency currents exert cytotoxic effects in NB69 human neuroblastoma cells but not in peripheral blood mononuclear cells.

Authors:  María Luisa Hernández-Bule; Ernesto Roldán; Joaquín Matilla; María Angeles Trillo; Alejandro Ubeda
Journal:  Int J Oncol       Date:  2012-07-24       Impact factor: 5.650

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.